HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM ) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $12.00 per share. The aggregate offering size was approximately $69.0 million, before deducting the underwriting discounts and commissions and other offering expenses.
Citigroup and Jefferies acted as lead book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann, Raymond James and SunTrust Robinson Humphrey acted as co-managers.
The securities described above were offered by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on February 1, 2016. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at http://www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Bellicum Pharmaceuticals, Inc.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. Bellicum is based in Houston, Texas.
Investors: Bellicum Pharmaceuticals, Inc. Alan Musso, CFO 832-384-1116 amusso@bellicum.com Media: BMC Communications Brad Miles, 646-513-3125 bmiles@bmccommunications.com
